While overall risks for adverse birth outcomes were not increased in children born to fathers who used disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, for autoimmune diseases in ...
Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...
The use of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for treating juvenile idiopathic arthritis (JIA) rose sharply from 2001 to 2022, while the use of ...
Biologic vs conventional DMARDs may offer cardioprotective benefits among patients with PsA, though an increased risk for infection requires vigilance.
Minimal disease activity (MDA) was more likely in people with psoriatic arthritis (PsA) when they initiated a disease-modifying anti-rheumatic drug (DMARD) earlier rather than later. That's according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results